BioStock: Phase II focus and further potential in Annexin´s Q2

In this year’s Q2 report, Annexin Pharmaceuticals emphasises intensive work with the phase II study within RVO, a great deal of interest for ANXV being seen from the industry, and that opportunities are also seen in the cancer area onwards. In the near future, new leaps are expected to be taken within both the phase II study and an imaging study for ANXV. Overall, CEO Anders Haegerstrand sees an exciting autumn ahead for the company.

Read the full article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2022/08/phase-ii-focus-and-further-potential-in-annexins-q2/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/